BR112013033544A2 - dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos - Google Patents

dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos

Info

Publication number
BR112013033544A2
BR112013033544A2 BR112013033544A BR112013033544A BR112013033544A2 BR 112013033544 A2 BR112013033544 A2 BR 112013033544A2 BR 112013033544 A BR112013033544 A BR 112013033544A BR 112013033544 A BR112013033544 A BR 112013033544A BR 112013033544 A2 BR112013033544 A2 BR 112013033544A2
Authority
BR
Brazil
Prior art keywords
paclitaxel
treatment
dosage
administration
gynecological cancers
Prior art date
Application number
BR112013033544A
Other languages
English (en)
Inventor
Macbeath Gavin
Tabah-Fisch Isabelle
Pearlberg Joseph
Moyo Victor
Kubasek William
Original Assignee
Merrimack Pharmaceuticals Inc
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc, Sanofi Sa filed Critical Merrimack Pharmaceuticals Inc
Publication of BR112013033544A2 publication Critical patent/BR112013033544A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

abstract provided are methods and compositions for clinical treatment of advanced gynecological cancers using anti-erbb3 antibodies combined with paclitaxel. tradução do resumo resumo patente de invenção: "dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos". são providos métodos e composições para tratamento clínico de cânceres ginecológicos avançados utilizando anticorpos anti-erbb3 combinados com paclitaxel.
BR112013033544A 2011-06-30 2012-06-13 dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos BR112013033544A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161503342P 2011-06-30 2011-06-30
US201161529630P 2011-08-31 2011-08-31
FR1250860 2012-01-30
US201261596102P 2012-02-07 2012-02-07
PCT/US2012/042164 WO2013003037A2 (en) 2011-06-30 2012-06-13 Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers

Publications (1)

Publication Number Publication Date
BR112013033544A2 true BR112013033544A2 (pt) 2017-12-19

Family

ID=47424747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033544A BR112013033544A2 (pt) 2011-06-30 2012-06-13 dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos

Country Status (15)

Country Link
US (1) US20140248280A1 (pt)
EP (1) EP2726100A4 (pt)
JP (1) JP2014527035A (pt)
KR (1) KR20140063578A (pt)
CN (1) CN103945866A (pt)
AU (1) AU2012275850A1 (pt)
BR (1) BR112013033544A2 (pt)
CA (1) CA2839869A1 (pt)
CO (1) CO6862110A2 (pt)
EA (1) EA201490180A1 (pt)
MA (1) MA35281B1 (pt)
MX (1) MX2013015333A (pt)
TW (1) TW201317002A (pt)
UY (1) UY34178A (pt)
WO (1) WO2013003037A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008656A (es) 2007-02-16 2009-11-10 Merrimack Pharmaceuticals Inc Anticuerpos contra erbb3 y usos de los mismos.
DK2544680T3 (en) 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
CN104755499B (zh) 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US20170291956A1 (en) * 2014-07-16 2017-10-12 David Livingston HER3 Inhibition in Low-grade Serous Ovarian Cancers
CA2983008A1 (en) 2015-04-17 2016-10-20 Merrimack Pharmaceuticals, Inc. Combination treatments with seribantumab
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
US20190091227A1 (en) 2016-03-15 2019-03-28 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073629A2 (en) * 2006-11-03 2008-06-19 Board Of Regents, The University Of Texas System Bifunctional predictors of cancer treatment sensitivity and resistance
MX2009008656A (es) * 2007-02-16 2009-11-10 Merrimack Pharmaceuticals Inc Anticuerpos contra erbb3 y usos de los mismos.
DK2544680T3 (en) * 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER

Also Published As

Publication number Publication date
UY34178A (es) 2013-01-31
CA2839869A1 (en) 2013-01-03
EP2726100A4 (en) 2015-04-29
TW201317002A (zh) 2013-05-01
WO2013003037A2 (en) 2013-01-03
CN103945866A (zh) 2014-07-23
WO2013003037A3 (en) 2014-05-01
MX2013015333A (es) 2014-07-09
CO6862110A2 (es) 2014-02-10
EA201490180A1 (ru) 2014-08-29
JP2014527035A (ja) 2014-10-09
US20140248280A1 (en) 2014-09-04
AU2012275850A1 (en) 2013-03-21
MA35281B1 (fr) 2014-07-03
KR20140063578A (ko) 2014-05-27
EP2726100A2 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
CY2019008I1 (el) Χρηση τροποποιημενων απο χιμαιρικο αντιγονικο υποδοχεα τ κυτταρων στη θεραπευτικη αγωγη καρκινου
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
CL2014002726A1 (es) Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14).
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EA201270722A1 (ru) Формы рифаксимина и их применение
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
MX2013011922A (es) Compuestos de benceno substituido.
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
MY162146A (en) Pharmaceutical composition
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
PH12015501609A1 (en) Phenicol antibacterials
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
IN2014DN09228A (pt)

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE FR 1250860, REIVINDICADA NO PCT/US2012/042164, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE UM DOS DEPOSITANTES CONSTANTES DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("MERRIMACK PHARMACEUTICALS, INC") SER DIVERGENTE DE UM DOS TITULARES DA PRIORIDADE REIVINDICADA ("MERRIMACK PHARMACEUTICALS") E, MESMO APOS A ELABORACAO DE EXIGENCIA PARA TAL, NAO FOI SANADA A DIVERGENCIA APONTADA. DESSA FORMA, RESTA NECESSARIA A APRESENTACAO DO DOCUMENTO COMPROBATORIO DE CESSAO DA CITADA PRIORIDADE ACOMPANHADO DE SUA RESPECTIVA TRADUCAO, O QUE NAO OCORR

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]